NHL
MCID: LYM143
MIFTS: 79

Lymphoma, Non-Hodgkin, Familial (NHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 57 29 6 37 39
Non-Hodgkin Lymphoma 57 12 73 58 36 29 6 15
Lymphoma, Non-Hodgkin 57 13 44 70
Nhl 57 58 72
Lymphoma, Non-Hodgkin, Somatic 57
Lymphoma, Follicular, Somatic 57
Familial Non-Hodgkin Lymphoma 72
Follicular Lymphoma, Somatic 6
Non-Hodgkin Lymphoma; Nhl 57
Lymphoma Non-Hodgkins 54
Non-Hodgkins Lymphoma 17
Lymphosarcoma 15

Characteristics:

Orphanet epidemiological data:

58
non-hodgkin lymphoma
Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0060060
OMIM® 57 605027
KEGG 36 H02418
MeSH 44 D008228
ICD10 32 C85.7 C85.9
MESH via Orphanet 45 D008228
UMLS via Orphanet 71 C0024305
Orphanet 58 ORPHA547
UMLS 70 C0024305

Summaries for Lymphoma, Non-Hodgkin, Familial

KEGG : 36 Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies worldwide. NHL includes malignant tumors of the lymphoid tissues variously resulting from the clonal growth of B cells, T cells and natural killer cells. NHL can be broadly classified based on the type of lymphocyte involved: B lymphocyte (B cell) or T lymphocyte (T cell) and is further classified by other factors, including whether it is aggressive or indolent. Aggressive NHL is fast-growing disease. It mainly includes mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma and peripheral T-cell lymphoma. On the other hand, indolent NHL is slow-growing disease. It mainly includes follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma and MALT lymphoma.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to lymphoma, mucosa-associated lymphoid type and mantle cell lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Epirubicin and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are lymphoma and cellular

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

UniProtKB/Swiss-Prot : 72 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

Wikipedia : 73 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphomas except... more...

More information from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1058)
# Related Disease Score Top Affiliating Genes
1 lymphoma, mucosa-associated lymphoid type 33.5 TP53 TNFRSF8 MYD88 MYC IRF4 BCL6
2 mantle cell lymphoma 33.4 TP53 PIK3CA MYC EZH2 BCL6 BCL10
3 mature t-cell and nk-cell lymphoma 33.2 TP53 TNFRSF8 MYC BCL6 ALK
4 lymphoplasmacytic lymphoma 33.2 MYD88 BCL6 B2M
5 leukemia, chronic lymphocytic 33.1 TP53 TNFRSF8 NRAS MYD88 MYC IRF4
6 reticulosarcoma 33.1 TNFRSF8 MYC BCL6 B2M ALK
7 lymphoma 33.0 TP53 TNFRSF8 RAD54B PRF1 PIK3CA MYD88
8 richter's syndrome 32.9 TP53 MYC IRF4
9 burkitt lymphoma 32.7 TP53 TNFRSF8 MYC IRF4 BCL6
10 myeloma, multiple 32.6 TP53 PIK3CA NRAS MYD88 MYC IRF4
11 lymphoma, hodgkin, classic 32.6 TNFRSF8 IRF4 BCL6 ALK
12 leukemia, acute myeloid 32.5 TP53 TNFRSF8 PRF1 PIK3CA NRAS MYC
13 lymphoblastic lymphoma 32.4 TP53 TNFRSF8 MYC BCL6
14 cll/sll 32.3 TP53 EZH2 BCL6
15 myelodysplastic syndrome 32.2 TP53 PRF1 NRAS MYC EZH2 B2M
16 acquired immunodeficiency syndrome 32.2 TP53 MYC BCL6 B2M
17 sarcoma 32.1 TP53 PIK3CA NRAS MYC BRAF ALK
18 diffuse large b-cell lymphoma 32.1 TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
19 skin carcinoma 32.1 TP53 PIK3CA NRAS MYC MAP2K1 BRAF
20 b-cell lymphoma 32.0 TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
21 kaposi sarcoma 32.0 TP53 PIK3CA MYC MAP2K1
22 central nervous system lymphoma 32.0 TP53 MYD88 MYC BCL6
23 lymphoproliferative syndrome 32.0 TNFRSF8 PRF1 NRAS CASP10 BCL6 ALK
24 hepatitis b 32.0 TP53 PIK3CA MYD88 MYC
25 hodgkin's lymphoma, lymphocytic-histiocytic predominance 32.0 TNFRSF8 BCL6
26 skin melanoma 31.9 TP53 PIK3CA NRAS MYC MAP2K1 EZH2
27 melanoma 31.9 TP53 PIK3CA NRAS MYC MAP2K1 EZH2
28 gastric lymphoma 31.9 TP53 IRF4 BCL6 BCL10
29 adenocarcinoma 31.9 TP53 RHOA PIK3CA MYC MAP2K1 BRAF
30 bone lymphoma 31.8 TNFRSF8 IRF4 BCL6 ALK
31 adult t-cell leukemia 31.8 TP53 TNFRSF8 MYC IRF4
32 breast lymphoma 31.8 TNFRSF8 IRF4 BCL6 ALK
33 testicular lymphoma 31.8 TNFRSF8 MYD88 IRF4 BCL6
34 angioimmunoblastic t-cell lymphoma 31.8 TNFRSF8 RHOA BCL6
35 lymphoma aids related 31.8 MYC BCL6
36 primary mediastinal large b-cell lymphoma 31.7 IRF4 BCL6
37 marginal zone b-cell lymphoma 31.7 TNFRSF8 MYD88 IRF4 BCL6 BCL10
38 follicular lymphoma 31.7 MYC IRF4 EZH2 BCL6 BCL10
39 glioblastoma 31.7 TP53 RHOA PIK3CA NRAS MYC BRAF
40 histiocytosis 31.6 TNFRSF8 NRAS MAP2K1 BRAF ALK
41 pediatric lymphoma 31.6 TNFRSF8 MYC IRF4 BCL6 ALK
42 adult lymphoma 31.6 TNFRSF8 MYC IRF4 BCL6 ALK
43 neuroblastoma 31.5 TP53 PIK3CA NRAS MYC MAP2K1 EZH2
44 leukemia, chronic myeloid 31.5 TP53 NRAS MYC IRF4 BRAF
45 peripheral t-cell lymphoma 31.4 TP53 TNFRSF8 RHOA BCL6 ALK
46 squamous cell carcinoma 31.4 TP53 RHOA PIK3CA MYC MAP2K1 BRAF
47 bladder cancer 31.4 TP53 PIK3CA NRAS MYC MAP2K1 EZH2
48 cholangiocarcinoma 31.4 TP53 PIK3CA EZH2 BRAF
49 lung cancer susceptibility 3 31.3 TP53 RHOA PIK3CA NRAS MYC MAP2K1
50 leukemia, acute lymphoblastic 31.3 TP53 TNFRSF8 MYC IRF4 BCL6

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

31
# Description HPO Frequency HPO Source Accession
1 lymphoma 31 HP:0002665

Clinical features from OMIM®:

605027 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 B2M BCL10 BCL6 BRAF EZH2 IRF4
2 homeostasis/metabolism MP:0005376 10.38 ALK B2M BCL6 BRAF EZH2 IRF4
3 endocrine/exocrine gland MP:0005379 10.37 ALK B2M BCL10 BCL6 BRAF EZH2
4 hematopoietic system MP:0005397 10.37 B2M BCL10 BCL6 BRAF EZH2 IRF4
5 growth/size/body region MP:0005378 10.36 ALK B2M BCL6 BRAF EZH2 IRF4
6 immune system MP:0005387 10.33 B2M BCL10 BCL6 BRAF EZH2 IRF4
7 cardiovascular system MP:0005385 10.3 B2M BCL6 BRAF EZH2 MAP2K1 MYC
8 mortality/aging MP:0010768 10.27 ALK B2M BCL10 BCL6 BRAF EZH2
9 embryo MP:0005380 10.24 B2M BCL10 BRAF EZH2 MAP2K1 MYC
10 integument MP:0010771 10.17 ALK B2M BCL6 BRAF EZH2 MAP2K1
11 neoplasm MP:0002006 10.1 ALK B2M BRAF EZH2 IRF4 MAP2K1
12 nervous system MP:0003631 10.03 ALK B2M BCL10 BRAF EZH2 MAP2K1
13 liver/biliary system MP:0005370 10.01 B2M BCL6 BRAF MYC MYD88 NRAS
14 no phenotypic analysis MP:0003012 9.7 BCL6 EZH2 MYC MYD88 NRAS PIK3CA
15 normal MP:0002873 9.65 ALK BCL6 BRAF EZH2 MAP2K1 MYC
16 reproductive system MP:0005389 9.32 ALK B2M BCL6 BRAF MAP2K1 MYC

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 507)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
3
Dacarbazine Approved, Investigational Phase 4 4342-03-4 5351166 2942
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Prilocaine Approved Phase 4 721-50-6 4906
8
Nitric Oxide Approved Phase 4 10102-43-9 145068
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
11
Pirarubicin Investigational Phase 4 72496-41-4
12 Anesthetics, General Phase 4
13 Anti-Arrhythmia Agents Phase 4
14 Sodium Channel Blockers Phase 4
15 Diuretics, Potassium Sparing Phase 4
16 Lidocaine, Prilocaine Drug Combination Phase 4
17 Anesthetics, Inhalation Phase 4
18 Hematinics Phase 4
19 Epoetin alfa Phase 4 113427-24-0
20
Allopurinol Approved Phase 3 315-30-0 2094
21
Zoledronic Acid Approved Phase 3 118072-93-8 68740
22
Calcium carbonate Approved, Investigational Phase 3 471-34-1
23
Rasburicase Approved, Investigational Phase 3 134774-45-1
24
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
25
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
26
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
27
Lenograstim Approved, Investigational Phase 3 135968-09-1
28
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
29
Mycophenolic acid Approved Phase 3 24280-93-1 446541
30
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
31
Famotidine Approved Phase 3 76824-35-6 3325
32
Vinblastine Approved Phase 3 865-21-4 241903 13342
33
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
34
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
35
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
39
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
40
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
41
Idarubicin Approved Phase 3 58957-92-9 42890
42
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
43
Mercaptopurine Approved Phase 3 50-44-2 667490
44
Pegaspargase Approved, Investigational Phase 3 130167-69-0
45
Ichthammol Approved Phase 3 8029-68-3
46
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
47
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
48
Mesna Approved, Investigational Phase 3 3375-50-6 598
49
ofatumumab Approved Phase 3 679818-59-8 6918251
50
leucovorin Approved Phase 3 58-05-9 6006

Interventional clinical trials:

(show top 50) (show all 1802)
# Name Status NCT ID Phase Drugs
1 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
2 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
5 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
7 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
8 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
9 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
10 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
11 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
12 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
13 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
14 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
15 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
16 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
17 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
18 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
19 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
20 Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
21 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Recruiting NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
22 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
23 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
24 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
25 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
26 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
27 A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
28 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
29 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
30 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
31 A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
32 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
33 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
34 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
35 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
36 Non-Hodgkin's Lymphoma T Cell Protocol Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
37 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
38 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
39 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
40 Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
41 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
43 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
44 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
45 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
46 Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies Unknown status NCT03623087 Phase 3 Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase
47 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
48 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
49 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
50 Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) - Safety Study in a General Autologous Transplant Population Completed NCT00838357 Phase 3 Generic = Plerixafor

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aldesleukin
bendamustine
Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cladribine
fludarabine
Fludarabine phosphate
Ifosfamide
Lomustine
mercaptopurine
pegaspargase
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, non-hodgkin

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

# Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 29
2 Lymphoma, Non-Hodgkin, Familial 29 BCL10 CASP10 PRF1

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

40
T Cells, Bone Marrow, Bone, Breast, B Cells, Myeloid, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 12323)
# Title Authors PMID Year
1
Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. 6 54 61
12010812 2002
2
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 57 61
21796119 2011
3
Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. 61 57
15811955 2005
4
A proportion of patients with lymphoma may harbor mutations of the perforin gene. 61 57
15728124 2005
5
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
6
A tumour suppressor network relying on the polyamine-hypusine axis. 57
22722845 2012
7
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. 57
21390126 2011
8
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 57
20081860 2010
9
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 57
20054396 2010
10
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. 57
19412164 2009
11
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. 57
18323416 2008
12
BRAF mutations in non-Hodgkin's lymphoma. 6
14612909 2003
13
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
14
Inactivating mutations of the caspase-10 gene in gastric cancer. 6
11973654 2002
15
Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. 57
10651726 2000
16
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. 6
10362364 1999
17
Mutations in the RAD54 recombination gene in primary cancers. 6
10362365 1999
18
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
19
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. 6
1565144 1992
20
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 61 54
19965662 2010
21
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. 54 61
20038219 2010
22
An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. 54 61
19897031 2010
23
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. 54 61
19809881 2010
24
Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. 54 61
19821039 2010
25
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. 54 61
19748593 2010
26
Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. 61 54
20414345 2010
27
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 54 61
19917125 2009
28
Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. 61 54
19751723 2009
29
Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. 61 54
19396635 2009
30
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 61 54
19734146 2009
31
Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. 61 54
19811326 2009
32
[Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma]. 54 61
19954624 2009
33
Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. 61 54
19137297 2009
34
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. 54 61
19834627 2009
35
Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. 54 61
19452252 2009
36
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. 61 54
19388933 2009
37
BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. 61 54
19258594 2009
38
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. 54 61
19383901 2009
39
Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. 54 61
19100628 2009
40
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 54 61
19245433 2009
41
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. 61 54
19225536 2009
42
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. 54 61
18981293 2009
43
Targeting CD40 in Waldenström's macroglobulinemia. 61 54
19362983 2009
44
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. 61 54
19135941 2009
45
Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow. 54 61
18776814 2008
46
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. 61 54
18940680 2008
47
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. 61 54
18546271 2008
48
Primary tracheal lymphoma causing respiratory failure. 54 61
18670314 2008
49
Polymorphisms of human N-acetyltransferases and cancer risk. 61 54
18680472 2008
50
Serum CA125 and PSA concentrations in patients with lymphoma. 61 54
18654120 2008

Variations for Lymphoma, Non-Hodgkin, Familial

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

6 (show top 50) (show all 66)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCL10 NM_003921.5(BCL10):c.427_428dup (p.Glu145fs) Duplication Pathogenic 6253 rs587776632 GRCh37: 1:85733583-85733584
GRCh38: 1:85267900-85267901
2 BCL10 NM_003921.5(BCL10):c.231dup (p.Gly78fs) Duplication Pathogenic 6254 rs587776633 GRCh37: 1:85736415-85736416
GRCh38: 1:85270732-85270733
3 BCL10 NM_003921.5(BCL10):c.525_541del (p.Val176fs) Deletion Pathogenic 6255 rs587776634 GRCh37: 1:85733471-85733487
GRCh38: 1:85267788-85267804
4 BCL10 NM_003921.5(BCL10):c.410del (p.Asn137fs) Deletion Pathogenic 6256 rs587776635 GRCh37: 1:85733602-85733602
GRCh38: 1:85267919-85267919
5 BCL10 NM_003921.5(BCL10):c.398dup (p.Ser134fs) Duplication Pathogenic 6257 rs587776636 GRCh37: 1:85733613-85733614
GRCh38: 1:85267930-85267931
6 BCL10 NM_003921.5(BCL10):c.629_631AAG[2] (p.Glu212del) Microsatellite Pathogenic 6258 rs587776637 GRCh37: 1:85733375-85733377
GRCh38: 1:85267692-85267694
7 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg) SNV Pathogenic 13970 rs121913357 GRCh37: 7:140481403-140481403
GRCh38: 7:140781603-140781603
8 BRAF NM_001374258.1(BRAF):c.1526G>C (p.Gly509Ala) SNV Pathogenic 13971 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
9 RAD54B NM_012415.3(RAD54B):c.1778A>G (p.Asn593Ser) SNV Pathogenic 5638 rs114216685 GRCh37: 8:95403868-95403868
GRCh38: 8:94391640-94391640
10 RAD54L NM_003579.4(RAD54L):c.1331T>A (p.Val444Glu) SNV Pathogenic 6192 rs121908689 GRCh37: 1:46738430-46738430
GRCh38: 1:46272758-46272758
11 CASP10 NM_032976.3(CASP10):c.*327C>T SNV Pathogenic 7765 rs28936699 GRCh37: 2:202074111-202074111
GRCh38: 2:201209388-201209388
12 CASP10 NM_001230.5(CASP10):c.685-2146C>T SNV Pathogenic 7766 rs121909775 GRCh37: 2:202070652-202070652
GRCh38: 2:201205929-201205929
13 CASP10 NM_032976.3(CASP10):c.*128_*129insA Insertion Pathogenic 7767 rs398122800 GRCh37: 2:202073912-202073913
GRCh38: 2:201209189-201209190
14 B2M NM_004048.3(B2M):c.286G>A (p.Asp96Asn) SNV Pathogenic 31907 rs398122820 GRCh37: 15:45007839-45007839
GRCh38: 15:44715641-44715641
15 TP53 NM_000546.5(TP53):c.974G>T (p.Gly325Val) SNV Pathogenic 12367 rs121912659 GRCh37: 17:7576872-7576872
GRCh38: 17:7673554-7673554
16 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly) SNV Pathogenic 13972 rs121913338 GRCh37: 7:140453154-140453154
GRCh38: 7:140753354-140753354
17 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala) SNV Likely pathogenic 376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
18 RHOA NM_001664.4(RHOA):c.13C>T (p.Arg5Trp) SNV Likely pathogenic 376519 rs1057519952 GRCh37: 3:49413010-49413010
GRCh38: 3:49375577-49375577
19 RHOA NM_001664.4(RHOA):c.14G>T (p.Arg5Leu) SNV Likely pathogenic 376521 rs1057519953 GRCh37: 3:49413009-49413009
GRCh38: 3:49375576-49375576
20 RHOA NM_001664.4(RHOA):c.14G>A (p.Arg5Gln) SNV Likely pathogenic 376520 rs1057519953 GRCh37: 3:49413009-49413009
GRCh38: 3:49375576-49375576
21 RHOA NM_001664.4(RHOA):c.125A>C (p.Tyr42Ser) SNV Likely pathogenic 376523 rs1057519954 GRCh37: 3:49412898-49412898
GRCh38: 3:49375465-49375465
22 PIK3CA NM_006218.4(PIK3CA):c.1031T>G (p.Val344Gly) SNV Likely pathogenic 376497 rs1057519941 GRCh37: 3:178921549-178921549
GRCh38: 3:179203761-179203761
23 RHOA NM_001664.4(RHOA):c.125A>T (p.Tyr42Phe) SNV Likely pathogenic 376524 rs1057519954 GRCh37: 3:49412898-49412898
GRCh38: 3:49375465-49375465
24 PIK3CA NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala) SNV Likely pathogenic 376499 rs1057519941 GRCh37: 3:178921549-178921549
GRCh38: 3:179203761-179203761
25 RHOA NM_001664.4(RHOA):c.125A>G (p.Tyr42Cys) SNV Likely pathogenic 376522 rs1057519954 GRCh37: 3:49412898-49412898
GRCh38: 3:49375465-49375465
26 PIK3CA NM_006218.4(PIK3CA):c.1030G>A (p.Val344Met) SNV Likely pathogenic 376498 rs1057519942 GRCh37: 3:178921548-178921548
GRCh38: 3:179203760-179203760
27 EZH2 NM_004456.5(EZH2):c.1937A>T (p.Tyr646Phe) SNV Likely pathogenic 76768 rs267601394 GRCh37: 7:148508727-148508727
GRCh38: 7:148811635-148811635
28 EZH2 NM_004456.4(EZH2):c.1922A>C (p.Glu641Ala) SNV Likely pathogenic 376413 rs1057519894 GRCh37: 7:148508742-148508742
GRCh38: 7:148811650-148811650
29 EZH2 NM_004456.4(EZH2):c.1937A>C (p.Tyr646Ser) SNV Likely pathogenic 376218 rs267601394 GRCh37: 7:148508727-148508727
GRCh38: 7:148811635-148811635
30 EZH2 NM_004456.5(EZH2):c.1936T>C (p.Tyr646His) SNV Likely pathogenic 76769 rs267601395 GRCh37: 7:148508728-148508728
GRCh38: 7:148811636-148811636
31 EZH2 NM_004456.4(EZH2):c.1922A>T (p.Glu641Val) SNV Likely pathogenic 376412 rs1057519894 GRCh37: 7:148508742-148508742
GRCh38: 7:148811650-148811650
32 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Likely pathogenic 13899 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124
33 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 375876 rs121434596 GRCh37: 1:115258744-115258744
GRCh38: 1:114716123-114716123
34 EZH2 NM_004456.4(EZH2):c.1936T>A (p.Tyr646Asn) SNV Likely pathogenic 376217 rs267601395 GRCh37: 7:148508728-148508728
GRCh38: 7:148811636-148811636
35 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro) SNV Likely pathogenic 376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
36 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely pathogenic 12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
37 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro) SNV Likely pathogenic 376659 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
38 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe) SNV Likely pathogenic 12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
39 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu) SNV Likely pathogenic 376459 rs1057519918 GRCh37: 8:128750636-128750636
GRCh38: 8:127738390-127738390
40 TP53 NM_000546.5(TP53):c.614A>T (p.Tyr205Phe) SNV Likely pathogenic 376682 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
41 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
42 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile) SNV Likely pathogenic 376300 rs756091827 GRCh37: 8:128750681-128750681
GRCh38: 8:127738435-127738435
43 MAP2K1 NM_002755.3(MAP2K1):c.171G>C (p.Lys57Asn) SNV Likely pathogenic 376174 rs869025608 GRCh37: 15:66727455-66727455
GRCh38: 15:66435117-66435117
44 B2M NM_004048.3(B2M):c.2T>G (p.Met1Arg) SNV Likely pathogenic 376372 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
45 TP53 NM_000546.5(TP53):c.613T>G (p.Tyr205Asp) SNV Likely pathogenic 376686 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
46 B2M NM_004048.3(B2M):c.3G>A (p.Met1Ile) SNV Likely pathogenic 376368 rs1057519877 GRCh37: 15:45003747-45003747
GRCh38: 15:44711549-44711549
47 MYC NM_002467.6(MYC):c.217A>C (p.Thr73Pro) SNV Likely pathogenic 376458 rs750664148 GRCh37: 8:128750680-128750680
GRCh38: 8:127738434-127738434
48 TP53 NM_000546.5(TP53):c.614A>G (p.Tyr205Cys) SNV Likely pathogenic 376681 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
49 TP53 NM_000546.5(TP53):c.613T>C (p.Tyr205His) SNV Likely pathogenic 376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
50 B2M NM_004048.3(B2M):c.2T>C (p.Met1Thr) SNV Likely pathogenic 376371 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

72
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

Cosmic variations for Lymphoma, Non-Hodgkin, Familial:

9 (show top 50) (show all 4353)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM144183945 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.416G>A p.G139D 19:45072541-45072541 0
2 COSM85770123 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 19:45072541-45072541 0
3 COSM149262901 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4136C>T p.T1379M 16:72798546-72798546 0
4 COSM102021008 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1394C>T p.T465M 16:72798546-72798546 0
5 COSM87272037 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4136C>T p.T1379M 16:72798546-72798546 0
6 COSM152021784 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1474C>T p.P492S 18:724582-724582 0
7 COSM89892588 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1474C>T p.P492S 18:724582-724582 0
8 COSM136834701 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1489C>T p.P497S 18:724582-724582 0
9 COSM104881227 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
10 COSM101975701 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
11 COSM104234856 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
12 COSM92178757 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 0
13 COSM94288434 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 0
14 COSM108081754 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 0
15 COSM124861325 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1331C>G p.S444* 8:102257672-102257672 0
16 COSM127535674 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8126C>G p.S2709* 8:102257672-102257672 0
17 COSM87437165 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 8:102278924-102278924 0
18 COSM127546467 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6172G>A p.E2058K 8:102278924-102278924 0
19 COSM127061134 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 8:102257672-102257672 0
20 COSM87426596 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8144C>G p.S2715* 8:102257672-102257672 0
21 COSM127073052 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 8:102278924-102278924 0
22 COSM150369017 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4933C>T p.R1645C 16:2088116-2088116 0
23 COSM148995649 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4939C>T p.R1647C 16:2088116-2088116 0
24 COSM150586385 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4930C>T p.R1644C 16:2088116-2088116 0
25 COSM150364733 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4993A>G p.T1665A 16:2088263-2088263 0
26 COSM150323538 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5083A>G p.T1695A 16:2088263-2088263 0
27 COSM136627256 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5029A>G p.T1677A 16:2088263-2088263 0
28 COSM151376044 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5191A>G p.T1731A 16:2088263-2088263 0
29 COSM102633805 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4936C>T p.R1646C 16:2088116-2088116 0
30 COSM87039775 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5197A>G p.T1733A 16:2088263-2088263 0
31 COSM102629191 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4996A>G p.T1666A 16:2088263-2088263 0
32 COSM151378610 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5131C>T p.R1711C 16:2088116-2088116 0
33 COSM148991145 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4999A>G p.T1667A 16:2088263-2088263 0
34 COSM151519737 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5062C>T p.R1688C 16:2088116-2088116 0
35 COSM150328184 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4936C>T p.R1646C 16:2088116-2088116 0
36 COSM110119485 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4828C>T p.R1610C 16:2088116-2088116 0
37 COSM151755180 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5008C>T p.R1670C 16:2088116-2088116 0
38 COSM110113382 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4888A>G p.T1630A 16:2088263-2088263 0
39 COSM90413881 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5128A>G p.T1710A 16:2088263-2088263 0
40 COSM150583324 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4990A>G p.T1664A 16:2088263-2088263 0
41 COSM151752656 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5068A>G p.T1690A 16:2088263-2088263 0
42 COSM101190485 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4852A>G p.T1618A 16:2088263-2088263 0
43 COSM149819699 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5005C>T p.R1669C 16:2088116-2088116 0
44 COSM147711561 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5008C>T p.R1670C 16:2088116-2088116 0
45 COSM87045821 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5137C>T p.R1713C 16:2088116-2088116 0
46 COSM90419991 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5068C>T p.R1690C 16:2088116-2088116 0
47 COSM136632907 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.4969C>T p.R1657C 16:2088116-2088116 0
48 COSM147706018 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5056A>G p.T1686A 16:2088263-2088263 0
49 COSM149813473 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5065A>G p.T1689A 16:2088263-2088263 0
50 COSM151517921 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5122A>G p.T1708A 16:2088263-2088263 0

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CNTRL Non-Hodgkin''s lymphomas

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TP53 TNFRSF8 RHOA PIK3CA NRAS MYD88
2
Show member pathways
13.89 TP53 TNFRSF8 RHOA NRAS MYC MAP2K1
3
Show member pathways
13.61 TP53 RHOA PIK3CA NRAS MYC MAP2K1
4
Show member pathways
13.28 TP53 RHOA NRAS MYD88 MYC MAP2K1
5
Show member pathways
13.25 TP53 TNFRSF8 PIK3CA NRAS MYD88 MYC
6
Show member pathways
13.23 TP53 RHOA PIK3CA NRAS MYD88 MYC
7
Show member pathways
12.97 TP53 RHOA PIK3CA NRAS MYD88 MYC
8
Show member pathways
12.94 TP53 RHOA PIK3CA NRAS MYC MAP2K1
9
Show member pathways
12.9 TP53 PIK3CA MYD88 MYC MAP2K1 B2M
10 12.86 TP53 RHOA PIK3CA NRAS MYC MAP2K1
11 12.84 TP53 NRAS MYD88 MYC MAP2K1 BRAF
12
Show member pathways
12.84 TP53 PIK3CA NRAS MYC MAP2K1 BRAF
13
Show member pathways
12.81 RHOA PIK3CA MYD88 MYC MAP2K1
14
Show member pathways
12.8 RHOA PIK3CA NRAS MAP2K1 BRAF
15
Show member pathways
12.79 TP53 RHOA PIK3CA NRAS MAP2K1 BRAF
16
Show member pathways
12.76 TP53 PIK3CA NRAS MAP2K1 BRAF ALK
17 12.71 RHOA PIK3CA NRAS MAP2K1 BRAF
18
Show member pathways
12.7 TP53 PIK3CA NRAS MYC MAP2K1 BRAF
19 12.65 TNFRSF8 MYD88 IRF4 BCL6 BCL10 B2M
20
Show member pathways
12.59 PRF1 PIK3CA NRAS MAP2K1 BRAF
21
Show member pathways
12.57 TP53 RHOA PIK3CA NRAS MAP2K1 BRAF
22
Show member pathways
12.56 RHOA PIK3CA NRAS MYC MAP2K1
23 12.55 TP53 RHOA PIK3CA NRAS MYC MAP2K1
24
Show member pathways
12.53 PIK3CA NRAS MAP2K1 BCL6 BCL10
25
Show member pathways
12.52 TP53 PIK3CA NRAS MAP2K1 CASP10
26
Show member pathways
12.49 RHOA PIK3CA NRAS MYD88 MAP2K1
27 12.49 TP53 RHOA PIK3CA MYD88 BCL10
28
Show member pathways
12.48 RHOA PIK3CA NRAS MAP2K1 BRAF ALK
29
Show member pathways
12.47 RHOA PIK3CA NRAS MAP2K1
30
Show member pathways
12.47 TP53 RHOA PIK3CA NRAS MYC MAP2K1
31
Show member pathways
12.46 RHOA PIK3CA MAP2K1 BRAF
32
Show member pathways
12.46 TP53 PIK3CA MYC MAP2K1
33 12.4 RHOA PIK3CA MAP2K1 BRAF
34
Show member pathways
12.39 RHOA PIK3CA MYC MAP2K1
35 12.39 TP53 PIK3CA NRAS MYC MAP2K1 B2M
36
Show member pathways
12.37 TP53 PIK3CA MYD88 MAP2K1
37 12.36 TP53 RHOA PIK3CA NRAS
38
Show member pathways
12.36 PIK3CA MYD88 MYC MAP2K1
39
Show member pathways
12.36 TP53 NRAS MAP2K1 BRAF
40
Show member pathways
12.34 RHOA PIK3CA NRAS MYC MAP2K1 BRAF
41
Show member pathways
12.31 TP53 PIK3CA NRAS MYC MAP2K1 BRAF
42 12.3 RHOA MYD88 CASP10 BCL10
43 12.3 RHOA PIK3CA NRAS MAP2K1
44
Show member pathways
12.3 RHOA PIK3CA NRAS MYD88 MAP2K1 IRF4